The likelihood of developing a metastatic brain tumor depends on the type of cancer a patient has and how advanced it is. Lung, breast, melanoma, colon and kidney cancers commonly spread to the brain. This happens when the cancer cells at the primary site separate and enter the blood system. The secondary tumor is most often identified when a patient has a brain scan because they are experiencing neurological symptoms – usually headache and/or seizures. The treatment approach includes targeting the actual tumors, as well as the symptoms caused.
As a leader in cancer research, Bristol-Myers Squibb recognizes the serious challenges faced by patients with cancer metastatic to the brain. We strive to advance our scientific understanding of these complex cancer cases and are focused on developing Immuno-Oncology (I-O) therapies that can potentially help treat them.